IbisVision is a technology company.
IbisVision has raised $6.0M across 1 funding round.
IbisVision has raised $6.0M in total across 1 funding round.
IbisVision has raised $6.0M in total across 1 funding round.
IbisVision's investors include Deepbridge Capital, Richard Thompson.
IbisVision is a UK-based technology company founded in 2014 that develops a cloud-based vision testing platform for eyecare professionals and patients.[1] It offers remote tools like online vision tests (visual acuity, color, visual field, Amsler), refractions, and self-guided prescription checks via products such as IbisEngage (clinician-led) and Ibis Re-Check (patient self-serve), serving the optical industry to connect optometrists and patients efficiently.[1][2][3] The platform solves clinician shortages and access issues by enabling remote exams, reducing in-office time, and optimizing resource distribution, with $5.66M raised in Series A funding and recent U.S. market expansion.[1]
Growth momentum includes platform expansions from single tests to comprehensive suites, strategic partnerships with eyecare operators, and launches like Ibis Re-Check at Vision Expo East, positioning it in the digital health space with a Mosaic Score up +20 points recently.[1]
IbisVision emerged in 2014 in Glasgow, U.K., addressing growing demand for eyecare amid clinician shortages by pioneering internet-based eye tests.[1][3] While specific founders are not detailed in available sources, CEO Mark Roger has led its evolution, emphasizing flexible, location-independent testing to mirror models like Uber for clinical resources.[3] Early traction built on a single-test platform, expanding to multiple exams on a secure, intuitive SaaS model with database and communications tools, gaining interest from eyecare operators and achieving Series A funding ($5.66M, last raised about a year ago).[1][2][3][5]
Pivotal moments include widening strategy to link remote clinicians globally, boosting doctor availability, and recent U.S. entry with validated remote refraction systems.[1][3]
IbisVision rides the digital health and telehealth wave in eyecare, capitalizing on post-pandemic remote care demand, clinician shortages, and rising eye health needs from aging populations and screen time.[1][3] Timing aligns with regulatory progress for remote refractions (undergoing U.S. validation) and market forces like flexible work models, enabling global talent pooling akin to gig economy platforms.[1][3] It influences the ecosystem by partnering with optical providers, reducing inefficiencies, and pushing adoption of internet-based diagnostics in a sector slow to digitize, as seen in its Expert Collection inclusion for digital health.[1][3]
IbisVision is poised for scaled U.S. growth with Re-Check and Engage, leveraging its validated tech to capture tele-eyecare market share amid clinician gaps.[1] Trends like AI-enhanced diagnostics, global telehealth expansion, and personalized eye care will shape its path, potentially amplifying influence through more operator integrations and feature expansions. As a Series A player with positive momentum, it could redefine accessible vision testing, efficiently linking pros and patients in a resource-strapped landscape.[1][3]
IbisVision has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Venture Round in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $6.0M Venture Round | Deepbridge Capital, Richard Thompson |